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1496Objective: Pulmonary function frequently deteriorates after cardiopulmonary bypass (CPB). Chronic obstruc-
tive pulmonary disease (COPD) increases risk of respiratory complications after CPB. Cysteinyl leukotrienes
are important mediators of respiratory dysfunction. Their role during cardiac surgery and its lung complications
is incompletely understood. We studied whether production of cysteinyl leukotrienes changes during and after
cardiac surgery with CPB and differs between patients with and without COPD.
Methods: Patients with (n¼ 9) andwithout (n¼ 10)moderate-to-severe COPD undergoing cardiac surgery with
CPB were prospectively included. Plasma and urinary cysteinyl leukotriene and leukotriene B4 concentrations
were measured by enzyme-linked immunosorbent assay after anesthesia induction, at end of CPB, after CPB,
and 2 hours after intensive care unit admission. Gas exchange and respiratory mechanics were also assessed.
Results: Patients with COPD had larger airway resistances after CPB and chest closure (P<.001), lower ratio of
arterial Po2 to inspired oxygen fraction at intensive care unit admission (215 37 vs 328 30 mmHg, P<.05),
and longer postoperative mechanical ventilation (13.7  5.8 vs 6.8 3.4 hours, P<.01). Urinary cysteinyl leu-
kotriene concentrations increased with time in both groups (P<.01), but more in patients with than without
COPD (P<.05). Plasma cysteinyl leukotriene concentrations increased significantly between baseline and in-
tensive care unit admission in patients with but not without COPD (P<.01). Concentrations of leukotriene B4 in
plasma and urine did not increase significantly with time and were not different between groups.
Conclusions: Release of cysteinyl leukotrienes increases during cardiac surgery with CPB and is larger in pa-
tients with than without COPD. This may be related to higher lung and airway production of cysteinyl leuko-
trienes and neutrophil activation in patients with COPD. (J Thorac Cardiovasc Surg 2011;141:1496-502)Supplemental material is available online.
Chronic obstructive pulmonary disease (COPD) ranks num-
ber 4 among the causes of death in the United States.1
COPD because atherosclerotic cardiovascular disease is
closely linked to smoking and affects 4% to 27% of pa-
tients undergoing coronary artery bypass grafting
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The Journal of Thoracic and Cardiovascular Surdependent predictor of in-hospital mortality3 and a risk fac-
tor for extubation failure and prolonged mechanical
ventilation,4 likely compounding with the respiratory dys-
function that follows cardiac surgery.5
Leukotrienes are 5-lipoxygenase metabolites of arachi-
donic acid predominantly synthesized by leukocytes. Cys-
teinyl leukotrienes (leukotrienes C4, D4, and E4) mediate
bronchoconstriction, vasoconstriction, and increase vascu-
lar permeability.6,7 Cysteinyl leukotriene inhibition is
used clinically mainly in the modulation of bronchocon-
striction in aspirin- and exercise-induced asthma.8 Patients
with moderate-to-severe COPD may benefit from cysteinyl
leukotriene inhibition, as shown by the attenuation of their
hypertonic saline solution–induced bronchoconstriction.9
Cysteinyl leukotrienes appear to be important in experimen-
tal10 and clinical acute lung injury.11 Previous studies
suggested increases in blood12 and urinary13 cysteinyl leu-
kotrienes during and after cardiac surgery with cardiopul-
monary bypass (CPB). Those studies, however, did not
address the association between COPD and blood or urinary
cysteinyl leukotriene levels, used high-dose aprotinin,12 and
were performed more than 10 years ago, when surgical
techniques and CPB system biocompatibility may well
have led to higher inflammatory responses than thosegery c June 2011
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
COPD ¼ chronic obstructive pulmonary disease
ICU ¼ intensive care unit
LTB4 ¼ leukotriene B4
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respiratory dysfunction after CPB14 and the significant per-
centage of patients with COPD undergoing cardiac surgery,
there is no information on the intraoperative and immediate
postoperative changes in cysteinyl leukotrienes during car-
diac surgery in patients with and without COPD.
Leukotriene B4 (LTB4), another 5-lipoxygenase product,
is a powerful endogenously synthesized chemotactic factor
for granulocytes that is involved in the accumulation of neu-
trophils in the airways in COPD.15 In cardiac surgery, in-
creases of LTB4 have been observed in bronchoalveolar
lavage fluid16 and blood during and after CPB.12,17,18
LTB4 has also been suggested as a key mediator of
postoperative acute respiratory failure.
We hypothesized that the systemic inflammatory response
to cardiac surgery with CPB exacerbates the chronic inflam-
mation present in patientswith COPD, leading to higher pro-
duction of cysteinyl leukotrienes in patientswithCOPD than
in thosewithout COPD. To test this hypothesis, wemeasured
both plasma and urinary levels of cysteinyl leukotrienes in
patients with andwithout COPD undergoing cardiac surgery
with CPB. We evaluated whether (1) the production of
cysteinyl leukotrienes is increased during cardiac surgery,
(2) the changes in cysteinyl leukotriene levels differ accord-
ing to the presence of COPD, and (3) changes in plasma and
urinary levels of LTB4 and in lung functionvariables parallel
changes in cysteinyl leukotriene levels.
MATERIALS AND METHODS
Study Subjects
This prospective, single-center study was approved by the institutional
review board of the Massachusetts General Hospital (approval number
2007P000164), and written, informed consent was obtained from all sub-
jects. Twentypatients undergoing cardiac surgerywithCPBbetweenAugust
2007 and August 2008 were studied: 10 patients with moderate or severe
COPD, as defined byGlobal Initiative for ChronicObstructive LungDisease
criteria,19 and 10 patients without COPD andwith no history of either smok-
ing or pulmonary disease (control group). Exclusion criteria were the pres-
ence of acute respiratory failure, previous diagnosis of asthma, and
emergency surgery. Patient disease severity at intensive care unit (ICU) ad-
missionwas assessedwith the SimplifiedAcute Physiologic Score 3 score.20
Aspirin treatment during the 7 days preceding surgery was recorded to ac-
count for its role as a confounding factor given its effects on the modulation
of the 5-lipoxygenase pathway through inhibition of cyclooxygenase.21
Procedures
Regular medication was maintained until surgery. Patients were medi-
cated in advance with midazolam hydrochloride (INN midazolam); under-The Journal of Thoracic and Carwent anesthesia induction with fentanyl and propofol; had anesthesia
maintenance with isoflurane, midazolam, and fentanyl; and had muscle pa-
ralysis induced with cisatracurium besylate (INN cisatracurium besilate) or
pancuronium bromide. Standard monitoring, including electrocardiogra-
phy, pulse oximetry, radial artery catheterization, and pulmonary artery
catheterization was performed. Patients were mechanically ventilated
with a tidal volume of 8 mL/kg, an inspired oxygen fraction of 1, and a pos-
itive end-expiratory pressure of 2.5 cm H2O, with respiratory rate adjusted
to maintain normocarbia. Ventilator parameters were kept constant before
and after CPB.
All procedures were performed through a median sternotomy. CPB was
performed with activated clotting time greater than 480 seconds, systemic
cooling to 30C to 33C, and ascending aortic cannulation. Venous cannu-
lation was performed with a single double-stage right atrial cannula in all
cases except that of patient 7, in whom direct cannulation of both the supe-
rior and inferior venae cavae was used. Cardiac arrest was achieved by cold
or warm blood antegrade and retrograde cardioplegia. The flow was main-
tained at 2.4 L/(min $m2), with a mean arterial pressure greater than 50mm
Hg. During CPB, the expiratory limb of the breathing circuit was opened to
the atmospherewith lungs passively deflated. Beforeweaning fromCPB, at
least 1 recruitment maneuver to a peak inspiratory pressure of 20 to 25 cm
H2O with direct visualization of lung expansion was performed.Cardiopulmonary Function Measurements
Hemodynamic measurements were systemic and pulmonary arterial
pressures, central venous pressure, and cardiac output. Respiratory mea-
surements included arterial blood gas values and respiratory system com-
pliance and airway resistance obtained with a respiratory analyzer
(NICO; Respironics, Philips Healthcare, Best, The Netherlands). All func-
tion measurements were performed at 5 time points: (1) after intubation but
before sternotomy (baseline), (2) after sternotomy but before CPB, (3) after
CPB but before chest closure, (4) after chest closure at the end of surgery,
and (5) 2 hours after arrival in the ICU.
Leukotriene Measurements
Blood and urine samples were drawn at 4 time points chosen to repre-
sent major phases: (1) after intubation but before sternotomy (baseline),
(2) at the end of CPB while still on extracorporeal circulation, (3) after
CPB but before chest closure, and (4) 2 hours after arrival in the ICU. Uri-
nary leukotrienes could not be measured in 1 patient with COPD (patient
13; Table E1) who had previously known chronic renal failure and became
anuric during surgery. Tracheal aspirates were sampled at baseline and af-
ter CPB only when required as part of the patient’s care.
Cysteinyl leukotrienes and LTB4 concentrations were measured with an
enzyme-linked immunosorbent assay (Neogen Corporation, Lexington,
Ky). Plasma sampleswere lipid extractedwith the C18 Sep-Pak light column
(Waters Corporation, Milford, Mass) before leukotriene measurement.
Urinary leukotriene concentrations were normalized to urinary creatinine
to account for urine dilution changes.13 Plasma leukotriene concentrations
were corrected for changes in plasma protein concentration at each time
point relative to baseline to take into account plasma dilution during surgery.Statistical Analysis
All results are expressed as mean  SD or median with interquartile
range (25th–75th percentile). Because of the paucity of human data, we
based the power analysis for cysteinyl leukotriene measurements on animal
experiments.10 Considering a significance level of .05, a power of .8, and
a 2-sided hypothesis, we estimated that 8 patients in each study group
would be necessary. Statistical analysis was performed with SAS statistical
software (version 9; SAS Institute Inc, Cary, NC). Categoric variables were
compared with the c2 test or the Fisher Exact test as required. Continuous
data that were normally distributed were compared with the t test or other-
wise with the Mann–Whitney test. Two-way analysis of variance withdiovascular Surgery c Volume 141, Number 6 1497
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ferent time points. Bonferroni corrected post hoc tests were performed
when overall P value was less than .05.
RESULTS
Patients Characteristics at Baseline and During and
After Surgery
Nineteen patients (COPD n ¼ 9, no COPD n ¼ 10) were
included in the final analysis (Table E1). One patient with
COPD was excluded because of the intraoperative decision
to perform off-pump CABG. Patient demographic charac-
teristics and surgical procedures were distributed similarly
between groups (Table 1).
White blood cell counts increased dramatically between
baseline and ICU admission for both groups of patients
(Figure E1, A), with no significant difference between
groups. In the COPD group, there was a significant increase
in white blood cell counts from chest closure to 2 hours after
ICU admission. Platelet counts decreased significantly from
baseline to chest closure and from baseline to 2 hours after
ICU admission for both groups of patients (Figure E1, B),
with no difference between groups.
At ICU admission, both groups of patients had similar
Simplified Acute Physiologic Score 3 values, hemodynamic
values, and blood hemoglobin and urea nitrogen concentra-
tions (Table 1). Patients with COPD exhibited a lower arte-
rial pH (P<.03) and a higher arterial PCO2 (P<.03) than did
patients without COPD.
Patients with COPD had a longer duration of mechanical
ventilation than did patients without COPD (13.7  5.8 vs
6.8  3.4 hours, P< .01; Table E2). At ICU admission,
plasma cysteinyl leukotriene levels of patients who required
mechanical ventilation for longer than 10 hours tended to be
higher than those of patients who did not (4.0 1.0 vs 2.3TABLE 1. Patient characteristics at intensive care unit admission
COPD
(n ¼ 9)
No COPD
(n ¼ 10)
P
value
Age (y, mean  SD) 69  9 64  11 .24
No. male 7 6 .72
CABG (No.) 7 6 .72
Bypass time (min, mean  SD) 123  41 118  56 .81
Aortic crossclamp time
(min, mean  SD)
86  27 85  37 .94
Simplified Acute Physiologic
Score 320 (mean  SD)
51  10 47  7 .24
Cardiac output (L/min, mean  SD) 4.0  1.3 4.2  1.0 .59
Heart rate (beats/min, mean  SD) 87  5 86  5 .58
Arterial pH (mean  SD) 7.39  0.5 7.45  0.5 .03
Arterial PCO2 (mm Hg, mean  SD) 40  7 33  4 .03
Hemoglobin (g/dL, mean  SD) 10.2  0.9 10.4  1.3 .74
Blood urea nitrogen (mg/dL,
median and interquartile range)*
20 (12–26) 12 (10–16) .14
COPD, Chronic obstructive pulmonary disease. *P value according to Mann–Whit-
ney test.
1498 The Journal of Thoracic and Cardiovascular Sur1.9 ng/mL, P¼ .051). There was a higher, although not sta-
tistically significant, proportion of postoperative atrial fi-
brillation in patients with COPD than without (Table 2).
One patient in the COPD group (patient 18; Table E1)
died on postoperative day 17.
Gas Exchange and Respiratory Mechanics
The ratio of arterial PO2 to inspired oxygen fraction did
not differ at baseline between patients with and without
COPD. The ratio decreased significantly during surgery
(P< .001), with no difference between groups (Figure 1,
A). Patients with COPD, however, had significantly lower
ratios of arterial PO2 to inspired oxygen fraction than did pa-
tients without COPD 2 hours after ICU admission (215 37
vs 328  30 mm Hg, P<.05).
Trends in airway resistancewere significantly different in
the 2 groups (Figure 1, B). At baseline, mean airway resis-
tance was numerically but not statistically higher in patients
with COPD than in patients without COPD. Resistance in-
creased significantly with time (P<.001) and was higher in
patients with COPD than in patients without COPD both af-
ter CPB (9.7  2.7 vs 7.8  2.0 cm H2O/[L $ s], P<.001)
and after chest closure (13.2 2.9 vs 7.4 1.4 cmH2O/[L $
s], P<.001).
Compliance of the respiratory system did not signifi-
cantly differ between patients with COPD and patients
without COPD (Figure E2). Compliance increased signifi-
cantly in patients without COPD, however, before and after
CPB relative to baseline and after chest closure (P<.01).
Leukotriene Measurements
Cysteinyl leukotrienes. Plasma cysteinyl leukotriene con-
centrations (Figure 2, A) changed significantly with time
(P< .001). Starting from similar baseline values for both
groups (COPD 1.5  0.3 vs no COPD ¼ 2.0  0.3 ng/mL,
P ¼ .31), cysteinyl leukotrienes increased significantly be-
tween baseline and end of CPB in patients without COPD
(P< .05) and tended to increase significantly in patients
with COPD (P ¼ .08). Plasma cysteinyl leukotrienes in pa-
tients with COPD were significantly higher 2 hours after
arrival in the ICU than at baseline (P<.01) and after CPB
(P<0.1). Mean plasma cysteinyl leukotriene concentrations
were similar in patients who received aspirin (n¼ 13, 2.4
1.1 ng/mL) and in thosewho did not (n¼ 6, 2.2 0.7 ng/mL,
P ¼ .60).
Urinary cysteinyl leukotriene concentrations presented
a clearly different pattern in patients with and without
COPD (Figure 2, B). Values increased with time (P<.001)
andwere higher in patients with COPD than in patients with-
out COPD (P<.05 for effect of group). Starting from similar
values at baseline for both groups (COPD 0.5  0.1 vs no
COPD 0.5  0.1 ng/mg creatinine, P ¼ .66), post hoc tests
showed that cysteinyl leukotriene urinary concentrations
tended to be higher in patients with COPD than in patientsgery c June 2011
FIGURE 1. Ratio of arterial PO2 (PaO2) to inspired oxygen fraction
(FiO2;A) and airway resistances (Raw; B) of patients with chronic obstruc-
tive pulmonary disease (COPD, filled circles, n ¼ 9) and without chronic
obstructive pulmonary disease (non-COPD, open circles, n ¼ 10) at 5 ma-
jor interventional phases: before sternotomy (Baseline), before and after
cardiopulmonary bypass (CPB), after chest closure (chest closed), and 2
hours after intensive care unit admission (ICU). Horizontal bars represent
median values. Single asterisk indicates P<.05; double asterisk indicates
P<.01; triple asterisk indicates P<.001. P values are derived from 2-way
analysis of variance with repeated measurements, with Bonferroni adjust-
ments for multiple comparisons.
FIGURE 2. Plasma (A) and urinary (B) cysteinyl leukotriene concentra-
tions in patients with chronic obstructive pulmonary disease (COPD, filled
circles, n ¼ 9 for plasma and n ¼ 8 for urine samples) and without chronic
obstructive pulmonary disease (non-COPD, open circles, n ¼ 10) at 4 ma-
jor interventional phases: before sternotomy (Baseline), at the end of car-
diopulmonary bypass with continued extracorporeal circulation (End
CPB), after cardiopulmonary bypass but before chest closure (After
CPB), and 2 hours after intensive care unit admission (ICU). Horizontal
bars represent median values. Single asterisk indicates P<.05; double as-
terisk indicates P<.01; triple asterisk indicates P<.001. P values are de-
rived from 2-way analysis of variance with repeated measurements, with
Bonferroni adjustments for multiple comparisons.
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ng/mg creatinine,P¼ .08) and after CPB (3.4 0.8 vs 2.0
0.4 ng/mg creatinine, P ¼ .06).
Leukotriene B4. Plasma LTB4 concentrations tended to in-
crease with time (P ¼ .06) after similar group values at
baseline (COPD 2.1  0.5 vs no COPD 2.2  0.7 ng/mL,
P ¼ .93), with no effect of group (Figure E3, A). MeanThe Journal of Thoracic and Carplasma LTB4 concentrations were equivalent in patients
who received aspirin (n¼ 13, 2.6 1.9 ng/mL) and in those
who did not (n ¼ 6, 3.0  1.8 ng/mL, P ¼ .65). Urinary
LTB4 concentrations were not affected by time or group
(Figure E3, B).
Tracheal aspirates. Tracheal aspirates were examined in
only 8 patients with COPD. Concentrations of cysteinyldiovascular Surgery c Volume 141, Number 6 1499
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tween baseline (18.7  7.8 ng/mL) and after CPB (24.9 
8.5 ng/mL, P¼ .35; Figure E4, A). LTB4 levels were similar
at baseline (8.9  2.3 ng/mL) and after CPB (9.7  2.2 ng/
mL, P ¼ .19; Figure E4, B). Tracheal aspirate concentra-
tions were approximately 9.1 times higher than plasma con-
centrations for cysteinyl leukotrienes and 3.3 times higher
for LTB4.
DISCUSSION
The main results of this study are as follows: (1) Patients
with COPD had higher airway resistances, poorer oxygen-
ation on ICU admission, and longer duration of mechanical
ventilation than did patients without COPD. (2) There was
a significant increase in cysteinyl leukotriene production in
the perioperative period of cardiac surgery with CPB. (3)
This increase was greater in patients with COPD than in pa-
tients without COPD, as quantified by urinary cysteinyl leu-
kotrienes. (4) In contrast, LTB4 production did not increase
significantly with time in blood or urine samples and did not
differ between groups.
We observed poorer respiratorymechanics, lower oxygen-
ation, and longer duration of mechanical ventilation in
patients with COPD than in patients without COPD. These
findings are consistent with previous reports of respiratory
dysfunction during CABG and higher perioperative morbid-
ity in patients with COPD5,22,23 and emphasize the clinical
relevance of studying the mechanisms of postoperative
respiratory failure in this subgroup of patients. Reasons
for the worse lung function in patients with COPD, as
observed in this study, are likely to be multifactorial,
including atelectasis, hydrostatic pulmonary edema, and
the systemic inflammatory response syndrome. These
perioperative insults could exacerbate the chronic loss of
elastic recoil and airway obstruction in COPD.4
Time courses of white blood cell and platelet counts were
similar in the 2 groups, consistent with previous reports4,24
and suggesting that more severe pulmonary dysfunction in
patients with COPD was likely due to group differences
other than accumulation of those cells in the lungs.24
Systemic Release of Cysteinyl Leukotrienes During
CPB
We measured plasma and urinary levels of cysteinyl leu-
kotrienes to obtain a sequential picture of leukotriene pro-
duction. Because of the short half-life of plasma cysteinyl
leukotrienes (about 7 minutes in healthy human subjects),25
plasma levels are likely to reflect acute changes in systemic
cysteinyl leukotriene production. On the other hand, urinary
levels of cysteinyl leukotrienes characterize cumulative
production of systemic cysteinyl leukotrienes during the
preceding hours.25-27
We found a significant increase in cysteinyl leukotriene
production in the perioperative period of cardiac surgery1500 The Journal of Thoracic and Cardiovascular Surwith CPB, starting early in the intraoperative period at the
end of CPB. Comparison of our findings with the literature
is limited, because data are scarce on intraoperative changes
in cysteinyl leukotrienes during CPB and on simultaneous
blood and urinary cysteinyl leukotriene measurements.
Nonetheless, our results of higher urinary cysteinyl leuko-
trienes in the ICU than at baseline are consistent with the
findings of Allen and colleagues,13 who showed an in-
creased urinary production of leukotriene E4 in the days
after CABG surgery.
The finding of increased plasma cysteinyl leukotrienes at
the end of CPB relative to baseline suggests that the 5-lipox-
ygenase pathway is activated at or before this time point.
Accordingly, urinary cysteinyl leukotriene levels, which rep-
resent cumulative cysteinyl leukotriene production,25-27
tended to be larger at the end of CPB than at baseline,
suggesting that cysteinyl leukotriene production starts
before the end of CPB. This consistency between our
plasma and urinary measurements strengthens our finding
that an acute increase in the perioperative production of
cysteinyl leukotrienes occurs during cardiac surgery with
CPB.
Several factors could lead to increased cysteinyl leukotri-
ene production. First, activation of the alternative comple-
ment pathway through contact of blood with CPB circuits
results in increased adhesion of human neutrophils to the
endothelium,4 potentially resulting in increased production
of cysteinyl leukotrienes by neutrophils. Neutrophils also
have an ability to export leukotriene A4 (a common precur-
sor of LTB4 and cysteinyl leukotrienes) to platelets and en-
dothelial cells for conversion to leukotrienes.6 Finally, cell
types present in the coronary artery plaque (mast cells and
basophils, monocytes and macrophages, endothelial cells)
produce cysteinyl leukotrienes. For example, acute sys-
temic release of cysteinyl leukotrienes in coronary blood
occurs minutes after percutaneous transluminal coronary
angioplasty.21 Similarly, manipulation of diseased coronary
arteries during CABG could have promoted the release of
cysteinyl leukotrienes into the bloodstream.21 The decrease
in plasma cysteinyl leukotriene concentrations after coro-
nary reperfusion (after CPB), the similar number of
CABG cases in each group, and the equivalent pattern of
leukotriene changes in CABG and non-CABG cases sug-
gest that differential release of leukotrienes in CABG cases
was not a major factor in our study.
After CPB, plasma cysteinyl leukotriene concentrations
decreased to a nadir comparable to baseline values
(Figure 2,A), whereas urinary cysteinyl leukotriene concen-
trations were higher than at baseline (Figure 2, B). Such
observations reinforce the proposition that cysteinyl leuko-
triene production occurred predominantly during the CPB
period.
Importantly, the increase in urinary cysteinyl leukotri-
enes was greater in patients with COPD than in patientsgery c June 2011
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finding in the setting of cardiac surgery with CPB. Various
factors could contribute to this finding. Stimulated periph-
eral neutrophils of patients with COPD produce more leu-
kotriene C4 than do those of healthy subjects.
28 Cardiac
surgery and CPB have been associated with activation of
peripheral neutrophils in patients in vivo.29,30 Thus
neutrophil activation may have led to our observation of
enhanced cysteinyl leukotriene production in patients with
COPD. In addition, cysteinyl leukotrienes can also be
produced in the lungs, as previously shown in patients
with adult distress syndrome.11 Greater lung production
of cysteinyl leukotrienes in patients with COPD than in pa-
tients without COPD thus may have contributed to the
higher urinary cysteinyl leukotriene levels observed in the
COPD group.
Measurements of cysteinyl leukotrienes in tracheal aspi-
rates in 8 patients with COPD demonstrated high concentra-
tions, suggesting that cysteinyl leukotrienes were probably
at least in part produced in lungs (Figure E4, A). Further
studies comparing tracheal aspirate measurements of cys-
teinyl leukotrienes in patients with and without COPD are
needed to draw further conclusion regarding the sites of pro-
duction of cysteinyl leukotrienes during CPB.
Finally, our finding of a trend in the association between
plasma cysteinyl leukotriene levels on ICU admission and
duration of mechanical ventilation, in conjunction with all
other findings, allows us to speculate on a causal relation-
ship between cysteinyl leukotriene production and pulmo-
nary outcome. A specific interventional study will be
required to establish such causality.
Systemic Release of LTB4 During CPB
Plasma and urinary concentrations of LTB4 did not change
significantly with time (Figure E3). Data on production of
LTB4 during clinical and experimental CPB are conflicting,
with findings of both increased12,17 and unchanged31 levels
perioperatively. The discrepancy between our findings and
reports of increased blood neutrophil LTB4 generation
during CPB17 may be related to the use of distinct measure-
ment methods. Gadaleta and coworkers17 used in vitro as-
says to quantify the potential production of LTB4 after
incubating neutrophils with a calcium ionophore,6 instead
of assessing existing LTB4 plasma levels as we did. In addi-
tion, recent progress in the biocompatibility of CPB circuits
has reduced production of inflammatory mediators,32 poten-
tially including LTB4.
Limitations and Perspectives of Study
This single-center study has several limitations. Our re-
sults do not allow us to draw any cause–effect relationship
between cysteinyl leukotriene levels and pulmonary dys-
function. Perioperative respiratory dysfunction during car-
diac surgery is multifactorial. Specific inhibition of theThe Journal of Thoracic and Carcysteinyl leukotriene pathway would therefore be the best
method to assess its role in the pathophysiology of postop-
erative pulmonary dysfunction after CPB and in patients
with COPD. Available oral cysteinyl leukotriene receptor
antagonists significantly protect against bronchoconstric-
tion as early as 2 hours after administration and for as
long as 24 hours.9,33 A phase II randomized, controlled
study assessing the effect of such an intervention on the
incidence of postoperative pulmonary dysfunction thus
appears both feasible and desirable.
Aspirin therapy has previously been shown to increase
the production of 5-lipoxygenase metabolites (leukotrienes)
in vivo through inhibition of cyclooxygenase.21 Because we
did not measure cyclooxygenase metabolites,34 we are un-
able to quantify the magnitude of cyclooxygenase inhibi-
tion and any potential effect of aspirin on the production
of leukotrienes during cardiac surgery with CPB. Because
the same proportion of patients received aspirin in both
groups (Table E1) andmean concentrations of cysteinyl leu-
kotrienes and LTB4 were similar in patients who received
aspirin and in those who did not, it is unlikely that an aspirin
effect would explain our results.
Finally, this study included a small number of patients,
and most of the patients with COPD (n ¼ 8/9) were in
Global Initiative for Chronic Obstructive Lung Disease
stage IIa19 (force expiratory volume of at least 50% but
less than 80%). As such, shortcomings of a small, single-
center study apply, such as limited characterization of the
entire population of patients with and without COPD, po-
tential bias of the studied population, and inability to
directly extrapolate our results to other subgroups of pa-
tients with COPD.CONCLUSIONS
In conclusion, our study shows that systemic release of
cysteinyl leukotrienes increases with time during the perio-
perative period of cardiac surgery with CPB. This increase
is already apparent at the end of the CPB time. Patterns of
change in cysteinyl leukotrienes differ between patients
with and without COPD, with patients with COPD showing
higher urinary cysteinyl leukotriene levels in the periopera-
tive period. This difference may be related to higher lung
and airway production of cysteinyl leukotrienes and in-
creased activation of neutrophils in patients with COPD.
LTB4 production did not differ between patients with and
without COPD and did not increase with time.
We thank Dr Charles N. Serhan (Brigham and Women’s hospi-
tal, Harvard Medical School, Boston, Mass) for his precious sup-
port in analyzing and interpreting the data, Drs Eduardo L.
Costa and Juan Jose Nieves for their contribution with enzyme-
linked immunosorbent assay measurements, Dr Ivany Schettino
for collaboration in the study design, Dr Hui Zheng for reviewing
the statistical analysis, and Barbara Hill Pellegrini, RN, Lauradiovascular Surgery c Volume 141, Number 6 1501
Perioperative Management de Prost et al
P
MCollier, RN, Christine Angelini, RN, Rosemary Daggett, RN, Katy
Zanetti, RN, Susan Aylouche, RN, Adrianne Diamond, RN, Cindy
Cooney, RN, Trish Meyer, RN, Kerry Crisalli, RN, Beth
McLaughlin, RN, Sharon Zisk, RN, and Jennifer Mills, RN, for
their help with intraoperative blood samples.References
1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital
Stat Rep. 2008;56:1-120.
2. Gardner SC, Grunwald GK, Rumsfeld JS, Mackenzie T, Gao D, Perlin JB, et al.
Risk factors for intermediate-term survival after coronary artery bypass grafting.
Ann Thorac Surg. 2001;72:2033-7.
3. Clough RA, Leavitt BJ, Morton JR, Plume SK, Hernandez F, Nugent W, et al.
The effect of comorbid illness on mortality outcomes in cardiac surgery. Arch
Surg. 2002;137:428-33.
4. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute
respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg.
1999;68:1107-15.
5. Samuels LE, Kaufman MS, Morris RJ, Promisloff R, Brockman SK. Coronary
artery bypass grafting in patients with COPD. Chest. 1998;113:878-82.
6. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357:
1841-54.
7. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes
and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;
237:1171-6.
8. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the
treatment of asthma. Am J Respir Crit Care Med. 1998;157:1363-71.
9. Z€uhlke IE, Kanniess F, Richter K, Nielsen-Gode D, B€ohme S, J€orres RA, et al.
Montelukast attenuates the airway response to hypertonic saline in moderate-
to-severe COPD. Eur Respir J. 2003;22:926-30.
10. Caironi P, Ichinose F, Liu R, Jones RC, Bloch KD, Zapol WM. 5-Lipoxygenase
deficiency prevents respiratory failure during ventilator-induced lung injury. Am
J Respir Crit Care Med. 2005;172:334-43.
11. Matthay MA, Eschenbacher WL, Goetzl EJ. Elevated concentrations of leukotri-
ene D4 in pulmonary edema fluid of patients with the adult respiratory distress
syndrome. J Clin Immunol. 1984;4:479-83.
12. Denizot Y, Feiss P, Nathan N. Are lipid mediators implicated in the production of
pro- and anti-inflammatory cytokines during cardiopulmonary bypass graft with
extracorporeal circulation? Cytokine. 1999;11:301-4.
13. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced
excretion of urinary leukotriene E4 in coronary artery disease and after coronary
artery bypass surgery. Coron Artery Dis. 1993;4:899-904.
14. Christenson JT, Aeberhard JM, Badel P, Pepcak F, Maurice J, Simonet F, et al.
Adult respiratory distress syndrome after cardiac surgery. Cardiovasc Surg.
1996;4:15-21.
15. Corhay JL, Henket M, Nguyen D, Duysinx B, Sele J, Louis R. Leukotriene B4
contributes to exhaled breath condensate and sputum neutrophil chemotaxis in
COPD. Chest. 2009;136:1047-54.
16. Moloney ED, Mumby SE, Gajdocsi R, Cranshaw JH, Kharitonov SA,
Quinlan GJ, et al. Exhaled breath condensate detects markers of pulmonary in-
flammation after cardiothoracic surgery. Am J Respir Crit Care Med. 2004;
169:64-9.
17. Gadaleta D, Fahey AL, VermaM, KoW, Kreiger KH, Isom OW, et al. Neutrophil
leukotriene generation increases after cardiopulmonary bypass. J Thorac Cardi-
ovasc Surg. 1994;108:642-7.1502 The Journal of Thoracic and Cardiovascular Sur18. Utoh J, Yamamoto T, Miyauchi Y. Is an increase in neutrophil leukotriene-
generating capacity a specific phenomenon for cardiopulmonary bypass? J
Thorac Cardiovasc Surg. 1995;110:276-7.
19. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global
strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med.
2007;176:532-55.
20. Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS
3—From evaluation of the patient to evaluation of the intensive care unit. Part 2:
Development of a prognostic model for hospital mortality at ICU admission. In-
tensive Care Med. 2005;31:1345-55. Erratum in: Intensive Care Med. 2006;32:
796.
21. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leu-
kotrienes and lipoxin A4. Impact of aspirin therapy. Circulation. 1992;86:
56-63.
22. Staton GW, Williams WH, Mahoney EM, Hu J, Chu H, Duke PG, et al. Pulmo-
nary outcomes of off-pump vs on-pump coronary artery bypass surgery in a ran-
domized trial. Chest. 2005;127:892-901.
23. Cohen A, Katz M, Katz R, Hauptman E, Schachner A. Chronic obstructive pul-
monary disease in patients undergoing coronary artery bypass grafting. J Thorac
Cardiovasc Surg. 1995;109:574-81.
24. Brix-Christensen V, Tønnesen E, Hjortdal VE, Chew M, Flø C, Marqversen J,
et al. Neutrophils and platelets accumulate in the heart, lungs, and kidneys after
cardiopulmonary bypass in neonatal pigs. Crit Care Med. 2002;30:670-6.
25. Sala A, Voelkel N, Maclouf J, Murphy RC. Leukotriene E4 elimination and me-
tabolism in normal human subjects. J Biol Chem. 1990;265:21771-8.
26. Maclouf J, Antoine C, De Caterina R, Sicari R, Murphy RC, Patrignani P, et al.
Entry rate and metabolism of leukotriene C4 into vascular compartment in
healthy subjects. Am J Physiol. 1992;263(1 Pt 2):H244-9.
27. Denzlinger C, Guhlmann A, Scheuber PH, Wilker D, Hammer DK, Keppler D.
Metabolism and analysis of cysteinyl leukotrienes in the monkey. J Biol Chem.
1986;261:15601-6.
28. Mitsunobu F, Mifune T, Hosaki Y, Ashida K, Tsugeno H, Okamoto M, et al. En-
hanced production of leukotrienes by peripheral leukocytes and specific IgE an-
tibodies in patients with chronic obstructive pulmonary disease. J Allergy Clin
Immunol. 2001;107:492-8.
29. Evans BJ, Haskard DO, Finch JR, Hambleton IR, Landis RC, Taylor KM. The
inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in
vivo. J Thorac Cardiovasc Surg. 2008;135:999-1006.
30. Ilton MK, Langton PE, Taylor ML, Misso NL, Newman M, Thompson PJ, et al.
Differential expression of neutrophil adhesion molecules during coronary artery
surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118:
930-7.
31. Friedman M, Sellke FW, Wang SY, Weintraub RM, Johnson RG. Parameters of
pulmonary injury after total or partial cardiopulmonary bypass. Circulation.
1994;90(5 Pt 2):II262-8.
32. de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA,
Hack CE, et al. The impact of heparin-coated cardiopulmonary bypass circuits
on pulmonary function and the release of inflammatory mediators. Anesth Analg.
2004;98:1586-94. table of contents.
33. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, et al.
Onset and duration of protection against exercise-induced bronchoconstriction
by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97:
98-104.
34. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low
dose aspirin and inhibition of thromboxane B2 production in healthy subjects.
Thromb Res. 1980;17:317-27.gery c June 2011
FIGUREE1. White blood cell (A) and platelet (B) counts in patients with
chronic obstructive pulmonary disease (COPD, filled circles, n ¼ 9) and
without chronic obstructive pulmonary disease (non-COPD, open circles
n ¼ 10) at baseline before sternotomy (BL), after chest closure (CC), and
2 hours after intensive care unit admission (ICU). Horizontal bars represen
median values. Double asterisk indicates P<.01; triple asterisk indicates
P<.001.
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The Journal of Thoracic and CaFIGURE E2. Compliance of the respiratory system (Crs) in patients with
chronic obstructive pulmonary disease (COPD, filled circles, n ¼ 9) and
without chronic obstructive pulmonary disease (non-COPD, open circles,
n ¼ 10) at 5 major interventional phases: before sternotomy (Baseline),
before and after cardiopulmonary bypass (CPB), after chest closure (chest
closed), and 2 hours after intensive care unit admission (ICU). Horizontal
bars represent median values. Double asterisk indicates P< .01; triple
asterisk indicates P<.001. P values are derived from 2-way analysis of
variance with repeated measurements, with Bonferroni adjustments for
multiple comparisons.
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FIGUREE3. Plasma (A) and urinary (B) leukotriene B4 concentrations of
patients with chronic obstructive pulmonary disease (COPD, filled circles,
n¼ 9 for plasma and n¼ 8 for urine samples) and without chronic obstruc-
tive pulmonary disease (non-COPD, open circles, n ¼ 10) at 4 major
interventional phases: before sternotomy (Baseline), at the end of cardio-
pulmonary bypass with continued extracorporeal circulation (End CPB),
after cardiopulmonary bypass but before chest closure (After CPB), and
2 hours after intensive care unit admission (ICU). Horizontal bars represent
median values.
FIGURE E4. Cysteinyl leukotrienes (A) and leukotriene B4 (B) tracheal
aspirate concentrations in 8 patients with COPD before sternotomy (Base-
line) and after cardiopulmonary bypass (CPB). Horizontal bars represent
median values.
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TABLE E1. Patient characteristics
Case Sex Age (y) COPD GOLD
Smoking
(pack-y)
BMI
(kg/cm2) Aspirin
Inhaled
steroids
Preoperative chest
radiograph
Type of
surgery
1 M 81 No NA 0 27.1 Yes No Normal AVR, CABG 31
2 M 63 No NA 0 30.5 Yes No Normal CABG 32
3 F 71 No NA 0 28.1 No No Normal AVR
4 M 50 No NA 0 19.8 No No Normal ARR
5 M 73 No NA 0 26.5 Yes No Normal CABG 33
6 M 76 No NA 0 23.0 Yes No Normal CABG 33
7* M 53 No NA 0 22.6 No No Normal MVR
8 M 61 No NA 0 23.6 Yes No Normal CABG 33
9 F 53 No NA 0 24.5 Yes No Normal CABG 33
10 F 57 No NA 0 22.0 Yes No Normal LVMR
11 F 66 Yes IIa 150 34.1 Yes No Normal CABG 32
12 M 82 Yes IIb 65 21.8 No Yes P/E AVR
13 M 76 Yes IIa 60 25.8 Yes No Distention CABG 32
14 M 61 Yes IIa 90 18.5 No No Normal CABG 33
15 M 57 Yes IIa 80 26.9 Yes No Normal CABG 35
16 F 75 Yes IIa 100 43.3 Yes Yes Normal CABG 32
17 M 63 Yes IIa 120 37.3 No No P/E, CPE CABG 34
18 F 80 Yes IIa 50 30.3 Yes Yes P/E, CPE AVR, CABG 33
19 M 65 Yes IIa 150 18.0 Yes Yes Distention MVR
COPD, Chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease classification19; BMI, body mass index;M,male; NA, not appli-
cable; AVR, aortic valve repair;CABG, coronary artery bypass grafting; F, female; ARR, aortic root replacement;MVR,mitral valve repair; LV, left ventricular mass resection;P/E,
pleural effusion; CPE, cardiogenic pulmonary edema. *Venous access for cardiopulmonary bypass was performed with direct cannulation of both superior and inferior venae
cavae.
TABLE E2. Hospital course of patients with and without chronic obstructive pulmonary disease
COPD (n ¼ 9) No COPD (n ¼ 10) P value
Duration of mechanical ventilation (h, mean  SD) 13.7  5.8 6.8  3.4 <.01
Duration of intensive care unit stay
(d, median and interquartile range)*
2 (1–3) 1 (1–3) .27
Postoperative atrial fibrillation (no.) 7 (78%) 3 (30%) .24
Postoperative pneumonia (no.) 1 (11%) 0 (0%) >.999
In-hospital mortality (no.) 1 (11%) 0 (0%) >.999
COPD, Chronic obstructive pulmonary disease. *P value according to Mann–Whitney test.
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